• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Tiny magnetic implant delivers drug locally

February 14, 2017 By Sarah Faulkner

Tiny magnetic implant delivers drug locallyResearchers from the University of British Columbia have developed a magnetic drug implant that measures just 6 millimeters in diameter and can deliver a drug locally to a targeted tissue. The team’s work was published in the journal Advanced Functional Materials.

The device is a silicone sponge with magnetic carbonyl iron particles, wrapped in a round polymer layer. After the device is loaded with drug, it is surgically implanted into the area being treated. To activate the device, researchers passed a magnet over the patient’s skin and deformed the sponge, initiating the drug’s release into surrounding tissue through a small opening.

“Drug implants can be safe and effective for treating many conditions, and magnetically controlled implants are particularly interesting because you can adjust the dose after implantation by using different magnet strengths. Many other implants lack that feature,” co-author Ali Shademani said in prepared remarks.

“This device lets you release the actual dose that the patient needs when they need it, and it’s sufficiently easy to use that patients could administer their own medication one day without having to go to a hospital,” co-author John Jackson added.

The team tested the implant on animal tissue using a prostate cancer drug known as docetaxel. Even after multiple trials, the researchers found that the device was able to deliver the drug on demand.

They also concluded that drugs stored within the implant remain efficacious, as they produced an effect on cancer cells comparable to that of freshly administered docetaxel.

“This could 1 day be used for administering painkillers, hormones, chemotherapy drugs and other treatments for a wide range of health conditions. In the next few years we hope to be able to test it for long-term use and for viability in living models,” co-author Mu Chiao said.

Filed Under: Drug-Device Combinations, Featured, Implants, Research & Development Tagged With: University of British Columbia

IN CASE YOU MISSED IT

  • BD’s IV catheters plant in Utah marks 70 years
  • Novo taps Nanexa for long-acting obesity injectables with €1.17B pact
  • Abbott partners with Berry Street to add nutrition coaching to Lingo
  • Dexcom CFO to expand into COO role
  • Beta Bionics insulin patch pump scores FDA clearance

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS